Real-World Relevance, Support Tools, and Brand Differentiation Trend in the Q3 Antipsychotics MarketBiomarker-Driven Promotions and Emerging Therapeutics Spotlight Q3 AML Market

Promotional efforts in the antipsychotics market during the third quarter were reflected across both HCP and DTC materials, emphasizing brand differentiation, education initiatives, regulatory movement, and patient/HCP engagement strategies.

Otsuka and Lundbeck highlighted relatable narratives for the Abilify LAIs, using patient profiles to drive HCP adoption and DTC themes that emphasized long-term stability, while also sharing broader mental health education.

J&J took regulatory steps to expand Caplyta’s indication as a long-term schizophrenia treatment option, while Intra-Cellular Therapies updated professional resources via the ITCI Psych Center.

Cobenfy featured strong medical education efforts around its first anniversary, offered tools to support telehealth and initiation, and sought to empower caregivers with focused promotions.

Luye Pharma introduced Erzofri’s launch campaign, emphasizing its unique single-dose initiation to simplify LAI treatment and evidence-based comparability to other options.

Teva relayed Uzedy’s uptake in new prescriptions and regulatory progress toward a potential new indication, while promoting the use of LAIs, Uzedy’s valued benefits, and a campaign theme that evoked patient empowerment.

AbbVie introduced a new website for psychiatry medical education and released new insights highlighting HCP preferences and key patient concerns, while prioritizing formulary access and diagnostic differentiation of depressive symptoms.